Investor in pioneering radical longevity startups

Developing highly potent small-molecule senolytic therapeutics that activate the body’s immune surveillance to selectively clear senescent cells, advancing breakthrough treatments for aging and age-related diseases.

Leverages the innovative non-viral Fusogenix™ Proteo-Lipid Vehicle (PLV) platform for targeted extrahepatic delivery of genetic medicines, addressing age-related diseases like sarcopenia and obesity with enhanced precision, safety, and efficacy.

Developing a platform to rejuvenate and bank hematopoietic stem cells and as a result reboot the immune system. Advancing to phase I trials for chemotherapy patients.

Advancing USP30 inhibitors to trigger mitophagy and enhanced mitochondrial health with a robust science driven approach. These small molecules have the potential to address aging and neurodegeneration.

Accelerating protein engineering with an automated laboratory platform that reduces cost and time for designers. Working with industry leaders Adaptyv is set to lead the growing protein design market.

Looking to address the critical organ transplant shortage worldwide, this company is making significant research and engineering breakthroughs and generating novel IP.

Aiming to become the 'Function Health' of Europe by delivering data-driven, personalized longevity insights and interventions to the mainstream.